By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups, according to a new study. The ...

"The liver is an organ that is tremendously ... Hirst Professor of Oncology in Pathology and a member of the Meyer Cancer Center at Weill Cornell Medicine. "Reactivating the immune system is ...

Hirst III Professor of Oncology in Pathology and member of ... targets by studying what goes wrong in the liver's healing mechanisms that leads to cancer. Prior research has found that levels ...

Hirst III Professor of Oncology in Pathology and a member of ... targets by studying what goes wrong in the liver's healing mechanisms that lead to cancer. Prior research has found that levels ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

New hope for liver cancer patients: Biomarker may predict ... Hirst Professor of Oncology in Pathology and a member of the Meyer Cancer Center at Weill Cornell Medicine. "Reactivating the immune ...